Last reviewed · How we verify

Photocure — Portfolio Competitive Intelligence Brief

Photocure pipeline: 1 marketed, 0 filed, 0 Phase 3, 6 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 0 Phase 3 6 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
MAL MAL marketed Photosensitizing agent Protoporphyrin IX (via aminolevulinic acid pathway) Oncology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Galderma R&D · 2 shared drug classes
  2. DUSA Pharmaceuticals, Inc. · 1 shared drug class
  3. Joint Authority for Päijät-Häme Social and Health Care · 1 shared drug class
  4. Medical Dermatology Specialists · 1 shared drug class
  5. National Cancer Center, Korea · 1 shared drug class
  6. Novartis · 1 shared drug class
  7. Psoriasis Treatment Center of Central New Jersey · 1 shared drug class
  8. QLT Inc. · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Photocure:

Cite this brief

Drug Landscape (2026). Photocure — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/photocure. Accessed 2026-05-14.

Related